Trials / Completed
CompletedNCT00852202
Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression
A Double-blind, Placebo-controlled Study of RGH-188 (Cariprazine) in Bipolar Depression
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 234 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of cariprazine in the treatment of outpatients with bipolar depression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cariprazine | Drug: cariprazine (0.25 - 0.75 mg/day) |
| DRUG | cariprazine | Drug: cariprazine (1.5 - 3.0 mg/day) |
| DRUG | placebo | placebo capsules, oral administration, once daily dosing |
Timeline
- Start date
- 2009-06-30
- Primary completion
- 2010-06-15
- Completion
- 2010-06-15
- First posted
- 2009-02-26
- Last updated
- 2018-08-23
- Results posted
- 2018-08-23
Locations
26 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00852202. Inclusion in this directory is not an endorsement.